Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Core Points - Cytokinetics granted stock options, restricted stock units (RSUs), and performance stock units (PSUs) to 9 employees as a material inducement to their employment on December 31, 2024 [1][3] - The total granted includes 52,188 stock options, 33,885 RSUs, and 3,189 PSUs [1] Summary of Stock Options and RSUs - The RSUs will vest over 3 years, with 40% vesting on the first anniversary, another 40% on the second anniversary, and the final 20% on the third anniversary, contingent on continued service [2] - The stock options have an exercise price of $47.04 per share, equal to the closing price on the grant date, and will vest over 4 years, with 1/4 vesting on the one-year anniversary and the remainder vesting monthly over the next 36 months [2] - The stock options have a 10-year term [2] Summary of PSUs - The PSUs are subject to two performance goals, with up to 50% of the shares earned upon certification of the first goal and another 50% upon certification of the second goal [2] - Earned shares will vest as to 50% on the certification date and the remaining 50% after one year from the certification date, also contingent on continued service [2] Company Overview - Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on developing drug candidates targeting muscle biology for treating diseases with compromised cardiac muscle performance [4] - The company is preparing for the potential commercialization of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [4] - Other drug candidates in development include omecamtiv mecarbil for heart failure, CK-586 for heart failure with preserved ejection fraction, and CK-089 for muscular dystrophy and impaired skeletal muscle function [4]